Liu Peng, Zhang Jing, Wang Yun, Wang Chen, Qiu Xinping, Chen Dan-Qian
Shunyi Hospital, Beijing Hospital of Traditional Chinese Medicine, Beijing, China.
Institute of Plant Resources, Yunnan University, Kunming, China.
Front Pharmacol. 2022 Mar 4;13:800810. doi: 10.3389/fphar.2022.800810. eCollection 2022.
Renal fibrosis is the common and final pathological process of kidney diseases. As a dynamic and reversible post-translational modification, SUMOylation and deSUMOylation of transcriptional factors and key mediators significantly affect the development of renal fibrosis. Recent advances suggest that SUMOylation functions as the promising intervening target against renal fibrosis, and natural products prevent renal fibrosis modulating SUMOylation. Here, we introduce the mechanism of SUMOylation in renal fibrosis and therapeutic effects of natural products. This process starts by summarizing the key mediators and enzymes during SUMOylation and deSUMOylation and its regulation role in transcriptional factors and key mediators in renal fibrosis, then linking the mechanism findings of SUMOylation and natural products to develop novel therapeutic candidates for treating renal fibrosis, and concludes by commenting on promising therapeutic targets and candidate natural products in renal fibrosis via modulating SUMOylation, which highlights modulating SUMOylation as a promising strategy for natural products against renal fibrosis.
肾纤维化是肾脏疾病常见的最终病理过程。作为一种动态且可逆的翻译后修饰,转录因子和关键介质的SUMO化和去SUMO化显著影响肾纤维化的发展。最新研究进展表明,SUMO化是抗肾纤维化有前景的干预靶点,天然产物可通过调节SUMO化来预防肾纤维化。在此,我们介绍SUMO化在肾纤维化中的作用机制以及天然产物的治疗效果。这个过程首先总结SUMO化和去SUMO化过程中的关键介质和酶及其在肾纤维化中转录因子和关键介质的调控作用,然后将SUMO化和天然产物的机制研究结果联系起来,以开发治疗肾纤维化的新型候选药物,最后通过评论通过调节SUMO化在肾纤维化中有前景的治疗靶点和候选天然产物来得出结论,这突出了调节SUMO化作为天然产物抗肾纤维化的一种有前景的策略。